Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2 - Takeaways - MDSpire

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

  • By

  • Selim Chaib

  • José Alberto López-Domínguez

  • Marta Lalinde-Gutiérrez

  • Neus Prats

  • Ines Marin

  • Olga Boix

  • Andrea García-Garijo

  • Kathleen Meyer

  • María Isabel Muñoz

  • Mònica Aguilera

  • Lidia Mateo

  • Camille Stephan-Otto Attolini

  • Susana Llanos

  • Sandra Pérez-Ramos

  • Marta Escorihuela

  • Fatima Al-Shahrour

  • Timothy P. Cash

  • Tamara Tchkonia

  • James L. Kirkland

  • María Abad

  • Alena Gros

  • Joaquín Arribas

  • Manuel Serrano

  • May 29, 2026

  • 0 min

Share

  • 1

    A correction has been issued for the article published in Nature Cancer regarding intratumoral senescent cells.

  • 2

    The initial publication contained incorrect representative images for control and 5 μM palbociclib treatments.

  • 3

    The error was due to selecting images from a folder with multiple independent experiments.

  • 4

    Correct images for control and 5 μM treatments have been added to the amended figure.

  • 5

    An additional Source Data file with representative images for each experimental condition has been prepared.

Original Source(s)

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

  • by Selim Chaib, José Alberto López-Domínguez, Marta Lalinde-Gutiérrez, Neus Prats, Ines Marin, Olga Boix, Andrea García-Garijo, Kathleen Meyer, María Isabel Muñoz, Mònica Aguilera, Lidia Mateo, Camille Stephan-Otto Attolini, Susana Llanos, Sandra Pérez-Ramos, Marta Escorihuela, Fatima Al-Shahrour, Timothy P. Cash, Tamara Tchkonia, James L. Kirkland, María Abad, Alena Gros, Joaquín Arribas, Manuel Serrano

  • May 29, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Biotech exec Jeremy Levin on the industry’s strategic turning point